Joint AI-driven event prediction and longitudinal modeling in newly diagnosed and relapsed multiple myeloma

Researchers interested in creating a holistic view of a patient's disease state that will assist in physician decision-making developed a transformer-based machine learning model that jointly predicts progression-free survival, overall survival, and adverse events. It also forecasts key disease biomarkers, and assesses the effect of different treatment strategies, e.g., ixazomib, lenalidomide, dexamethasone (IRd) vs. lenalidomide, dexamethasone (Rd).